FDA review doesn't find increased bleeding risk with dabigatran

03/14/2013 | Forbes

Fears over serious bleeding risk associated with dabigatran as compared with warfarin can be tied to the increased awareness and vigilance and "stimulated reporting" involving a new drug, FDA officials concluded in a perspective published in the New England Journal of Medicine. Researchers said that in reviewing data from the FDA Adverse Event Reporting System, they found "no indication that dabigatran was not being used in accordance with its labeled directions." The review also did not find increased bleeding risk with dabigatran compared with warfarin.

View Full Article in:

Forbes

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ